RxDoctor Payments Data

James Abel, MD

Psychiatry · Fairmont, WVNPI 1376729244

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 29.8% of the total.

$1,021in general payments, 2019–2025

Across 76 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$304
  • Otsuka America Pharmaceutical, Inc.$228
  • Vanda Pharmaceuticals Inc.$145
  • AbbVie$142
  • Lundbeck LLC$66
  • Teva Pharmaceuticals USA, Inc.$48
  • plus $89 from 3 others

What the payments were for

  • Food & beverage$1,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,021 in reported general payments places this provider in the 70th percentile of 177 psychiatry providers in West Virginia.

See all psychiatry providers in West Virginia

Medicare billing

Part B allowed, 2024
$9,221
Medicare patients
51
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate44$133,892
Invega TrinzaPaliperidone Palmitate11$96,978
LatudaLurasidone Hcl11$23,419
VraylarCariprazine Hcl12$19,568
Paliperidone ErPaliperidone52$6,588
SaphrisAsenapine Maleate11$6,005
Clozapine94$5,517
MyrbetriqMirabegron12$5,046
BelsomraSuvorexant12$4,715
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine94$3,056
Risperidone OdtRisperidone24$3,027
Divalproex Sodium ErDivalproex Sodium28$2,803
Alprazolam267$2,427
Benztropine Mesylate156$2,251
Clonazepam245$2,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$304$230,87155 claims
AbbVieVraylar, Saphris$142$25,57323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 psychiatry providers in West Virginia.

Other psychiatry in Fairmont

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →